MD Anderson study: Targeting IL-6 could help relieve immunotherapy side effects

UCLA scientists identify clues to making immunotherapy more effective against glioblastoma

Two studies led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center provide insight into how the immune system can successfully be activated against glioblastoma while revealing why these therapies have historically fallen short.

October 16, 2026

Vol.52 No.38

Clinical Roundup

Wistar Institute study identifies immunotherapy strategy for glioblastoma

Scientists at the Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma. The researchers showed that reprogramming myeloid cells, a type of immune cell that glioblastoma tumors co-opt to protect themselves, while simultaneously boosting cancer-fighting T cells shrank the tumors and prevented them from coming back.

October 16, 2026

Vol.52 No.38

Clinical Regulatory News

MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy
“Because it works in one neural system, you begin to wonder: Well, what about another?”

For the past four decades, psilocybin research has focused on one area: the treatment of mental health disorders, including depression, anxiety, existential distress associated with serious medical illnesses, post-traumatic stress disorder, and addiction.

UT Austin study uncovers new driver of immunotherapy resistance in pancreatic cancer

Pancreatic tumors can resist immunotherapy by recruiting nearby immune cells to help protect them, according to researchers at The University of Texas at Austin. The findings, published in Nature Communications, also point to a potential new strategy for overcoming resistance and improving cellular therapies.

September 18, 2026

Vol.52 No.34

Clinical Roundup

Salk institue team discovers novel pathway, provides insights to combat immunotherapy resistance

Why do signaling proteins called interferons, which recruit the immune system to attack cancer cells, start helping the tumor grow rather than shrink when they linger too long?

September 18, 2026

Vol.52 No.34

Cancer leaders play “musical chairs” as executive jobs fill at top cancer centers
Lee replaces Pisters at MD Anderson, Tuveson moves to Duke, and Mitchell is named director at University of Florida

Change swept through executive offices at cancer centers in recent weeks, shifting top leadership at the University of Texas MD Anderson Cancer Center, Duke Cancer Institute, and the University of Florida.

September 11, 2026

Vol.52 No.33

By Paul Goldberg

MD Anderson study: Targeting IL-6 could help relieve immunotherapy side effects

YOU MAY BE INTERESTED IN

UCLA scientists identify clues to making immunotherapy more effective against glioblastoma

Wistar Institute study identifies immunotherapy strategy for glioblastoma

MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy
“Because it works in one neural system, you begin to wonder: Well, what about another?”

UT Austin study uncovers new driver of immunotherapy resistance in pancreatic cancer

Salk institue team discovers novel pathway, provides insights to combat immunotherapy resistance

Cancer leaders play “musical chairs” as executive jobs fill at top cancer centers
Lee replaces Pisters at MD Anderson, Tuveson moves to Duke, and Mitchell is named director at University of Florida

Renew today!

Subscriber content

Never miss an issue!

Login

MD Anderson study: Targeting IL-6 could help relieve immunotherapy side effects

YOU MAY BE INTERESTED IN

UCLA scientists identify clues to making immunotherapy more effective against glioblastoma

Wistar Institute study identifies immunotherapy strategy for glioblastoma

MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy“Because it works in one neural system, you begin to wonder: Well, what about another?”

UT Austin study uncovers new driver of immunotherapy resistance in pancreatic cancer

Salk institue team discovers novel pathway, provides insights to combat immunotherapy resistance

Cancer leaders play “musical chairs” as executive jobs fill at top cancer centersLee replaces Pisters at MD Anderson, Tuveson moves to Duke, and Mitchell is named director at University of Florida

Never miss an issue!

Login

MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy
“Because it works in one neural system, you begin to wonder: Well, what about another?”

Cancer leaders play “musical chairs” as executive jobs fill at top cancer centers
Lee replaces Pisters at MD Anderson, Tuveson moves to Duke, and Mitchell is named director at University of Florida